ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO587

Neutrophil Elastase-Deficient Mice Are Protected from Experimental Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibody Vasculitis

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • O'Sullivan, Kim M., Monash University, Clayton, Victoria, Australia
  • Gan, Poh-Yi, Monash University, Monash Medical Centre, Melbourne, Victoria, Australia
  • Kitching, A. Richard, Monash University, Monash Health, Clayton, Victoria, Australia
  • Holdsworth, Stephen R., Monash Health, Clayton, Victoria, Australia

Group or Team Name

  • Autoimmune Kidney Disease and Vasculitis Research Group
Background

Neutrophil extracellular trap (NETs) are implicated in the pathogenesis of myeloperoxidase anti neutrophil cytoplasmic antibody vasculitis (MPO-AAV). Neutrophil elastase (NE) is implicated in initiating NET formation through proteolytic degradation of the nuclear envelope, histone degradation and chromatin decondensation in concert with other neutrophil enzymes to facilitate DNA release. NETs are decorated with multiple proinflammatory enzymes including MPO (the autoantigen in this disease) and NE. NE released through degranulation is degraded by endogenous NE inhibitors, however NE bound to NET derived DNA is protected providing a reservoir of proteolytic NE enabling tissue destruction, microvascular injury and further recruitment of neutrophils. This study investigates the pathogenic contribution of NE release through NET formation in experimental MPO-AAV using animals deficient in neutrophil elastase.

Methods

A 20 day experimental model of anti-MPO GN was induced in B6.129X1-Elanetm1Sds/J mice (neutrophil elastase knock out mice) and wild-type (WT) litter mate controls by myeloperoxidase (MPO) immunisation and GN triggered using a sub-nephritogenic dose of anti-glomerular basement membrane globulin (anti GBM Ig), [n=10 (WT) and n=10 (Elane-/-)].

Results

Elane-/- animals were protected from excessive NET production and glomerular injury with significantly reduced numbers of glomerular neutrophils, extracellular MPO deposition, CD4 T cells and macrophages influx (all, P <0.05 compared to WT). Histological assessment of kidneys demonstrated a reduction in segmental necrosis in the Elane-/- group compared to the WT group (P<0.05). Functional injury measured by creatinine/albuminuria ratio was significantly reduced in the Elane -/- group compared to the WT group (P=0.04). Systemic autoimmunity to MPO was significantly reduced in Elane-/- mice with reduced frequency of MPO specific CD4 effector T cells from the draining lymph nodes and a significant reduction in dermal DTH, measured by a 24 hour footpad challenge with MPO (P<0.05, compared with WT).

Conclusion

Reduced NET formation in Elane -/- mice attenuated glomerular injury through the reduction in NET associated MPO and NE. This data provides proof of concept evidence that targeting NE therapeutically may be of potential benefit in MPO-AAV.